SK biopharmaceuticals earned a 39.2% operating margin in Q2 2026 on revenue of 247.4 billion won, an unusual result for a Korean drugmaker and a direct consequence of selling XCOPRI itself.
No news written yet.
| Period | 326030 | KOSPI | Difference |
|---|---|---|---|
| 1 week | -1.6% | -1.5% | -0.1% |
| 1 month | +8.5% | +5.2% | +3.4% |
| 3 months | -4.3% | -22.6% | +18.3% |
| 6 months | -11.2% | +31.3% | -42.5% |
| Year to date | -30.5% | +58.7% | -89.2% |
| 1 year | -19.1% | +108.9% | -128.0% |
Closed at 18% of the way from its 52-week low (₩74,600) to its 52-week high (₩140,700).
SK biopharmaceuticals discovered and now sells cenobamate, an epilepsy medicine marketed in the United States as XCOPRI, and it does so through its own American sales force rather than a licensing partner. That makes nearly all of its product revenue American, an unusual profile for a Korean pharmaceutical company. It is working to widen the drug's approved uses and to add other central nervous system assets behind it. US investors can evaluate the company largely from US prescription data they can already see.
| Sector | Biopharma | Employees | |
| Market | KOSPI | Founded | |
| Korean name | SK바이오팜 | Head office |
| Symbol | Last Price |
|---|---|
| 128940Hanmi Pharm. Co., Ltd. | ₩473,500 +2.8% |
| 000100Yuhan Corporation | ₩81,400 +0.0% |
| 028300HLB Co., Ltd. | ₩33,750 +2.9% |
| 298380ABL Bio Inc. | ₩71,400 +5.6% |
| 000250Samchundang Pharm | ₩157,000 +1.0% |
| 087010Peptron, Inc. | ₩157,300 +7.3% |
| 141080LigaChem Biosciences Inc. | ₩92,000 +4.2% |
| 145020Hugel, Inc. | ₩244,000 +1.5% |
| 302440SK Bioscience Co., Ltd. | ₩37,900 +0.4% |
| 009420Hanall Biopharma Co., Ltd. | ₩54,700 +1.5% |